Medicare Cuts Weight-Loss Drug Costs to $50 a Month

Starting July 1, seniors on Medicare facing obesity can finally afford medications that were once out of reach, thanks to a groundbreaking federal pilot program that slashes monthly costs from over $1,000 to just $50.

The Medicare GLP-1 Bridge program offers eligible seniors access to FDA-approved weight-loss drugs including Wegovy, Zepbound, and Foundayo. Previously, these same medications cost seniors between $1,086 and $1,650 per month when insurance wouldn't cover them for weight loss alone.

This marks a historic shift. For the first time ever, Medicare will cover GLP-1 medications when used solely for weight management, not just for treating diabetes or other conditions.

About 10 million Medicare beneficiaries live with obesity, many unable to afford treatments their doctors recommend. The program runs through the end of 2027, giving researchers time to study outcomes and determine long-term solutions.

To qualify, seniors need a body mass index of 35 or higher when starting treatment, or a BMI of 27 with another condition like heart disease or prediabetes. Those already receiving coverage for other conditions aren't eligible.

Dr. Mehmet Oz, who leads the Centers for Medicare and Medicaid Services, called the cost barrier "huge" for older Americans. "That ends today," he told reporters announcing the program.

The Ripple Effect spreads far beyond individual patients. When seniors can afford obesity treatment, they reduce risks for heart disease, stroke, and diabetes complications. Families spend less on emergency care and more on living well together.

Drug manufacturers Novo Nordisk and Eli Lilly partnered with the federal government to make the reduced pricing possible. The program also helps collect crucial data about how these medications work specifically for older adults.

Doctors will monitor participants carefully, as older patients sometimes experience more side effects from medications. Researchers at Northwestern found seniors on blood pressure drugs faced higher risks of dizziness and fainting when starting GLP-1s, making careful oversight essential.

The program opens doors for millions who've waited years for affordable access to treatments their doctors recommend. Jamey Millar from Novo Nordisk called it "a moment they and their families have been waiting for."

Federal officials plan to track participation closely to guide future decisions about permanent coverage.

For seniors who've struggled with obesity while watching medication prices soar beyond reach, July 1 brings genuine hope and tangible help.